Acme United earnings date
Acme United (UT1) Q3 2026 Earnings Report
DE:UT1 Q3 2026 EPS Results
- Actual EPS
- EUR 0.72
- Consensus EPS
- EUR 0.66
- Beat/Miss
- Beat by +EUR 0.06
- One Year Ago EPS
- EUR 0.42
DE:UT1 Q3 2026 Revenue Results
- Actual Revenue
- EUR 52.44M
- Expected Revenue
- EUR 50.97M
- Beat/Miss
- Beat by +EUR 1.47M
- YoY Revenue Growth
- +18.24%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/27/2026
- Time
- Before Open
- Conference Call
- Tuesday, October 27, 2026
Acme United's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Acme reported 18% quarterly sales growth, 80% net income growth, 74% earnings-per-share growth, improved gross margins, strong U.S. and international performance, positive My Medic contribution, expanding Spill Magic capacity, strong cash generation, and a favorable near-term outlook. The main challenges were higher SG&A, DMT closure costs, increased net debt and inventory, elevated freight and inflation, supply chain risks, and potential consumer pressure, but management described active measures to address these issues and continued growth opportunities for 2027.
Management said the fourth quarter is expected to be seasonally strong in both sales and earnings and that it is projecting a solid fourth quarter of 2026; savings from closing the DMT plant are expected to be over $1 million annually, beginning in January 2027, and the latest SmartCompliance First Aid kit is planned to begin shipping in January 2027. The company has already booked new business for 2027, expects normal promotions next year if conditions remain unchanged, and said that, if consumer conditions stay the same, it is looking at a very good 2027 with the Westcott business as well as First Aid. Management also said it expects sometime in the next 12 months there'll probably be another deal, noting that every year it winds up doing at least one, and that it personally thinks the company will bring inventory into cash during 2027.
- Strong Third-Quarter Sales GrowthNet sales were $58 million compared to $49.1 million in the third quarter of 2025, an increase of 18%. Excluding My Medic, sales increased 10%.
- Nine-Month Sales GrowthNet sales for the nine months ended September 30, 2026, were $173 million compared to $149 million in the same period in 2025, an increase of 16%. Excluding My Medic, sales increased 8%.
- Higher Net Income and Earnings Per ShareThird-quarter net income was $3.4 million, or $0.80 per diluted share, compared to $1.9 million, or $0.46 per diluted share, in 2025. Net income increased 80% and earnings per share increased 74%. Excluding the approximately $1 million net income impact from the tariff refund and related items, net income was $2.4 million, up 24%, and earnings per share were $0.55, up 20%.
- Nine-Month Profit ImprovementNet income for the first nine months of 2026 was $9.5 million, or $2.29 per diluted share, compared to $8.3 million, or $2.03 per diluted share, in the comparable period last year. Net income increased 14% and earnings per share increased 13%.
- Tariff Refund BenefitAcme received $6 million in IEEPA tariff refunds, recognized $4 million as a reduction of cost of goods sold, and recorded the remaining $2 million as an accrued liability. After reserves for the DMT facility closure and variable compensation, the net impact was $1.2 million in pre-tax income and approximately $1 million in after-tax income.
- Improved Gross MarginThird-quarter gross margin was 45.3% compared to 39.1% in 2025. The quarter included an approximately 690-basis-point benefit from the tariff refund, partially offset by approximately 310 basis points related to the DMT closure cost. First-nine-month gross margin was 42.6% compared to 39.8% in 2025, including a 230-basis-point tariff refund benefit partially offset by a 105-basis-point DMT closure impact.
- Favorable Product MixExcluding tariff refunds and the DMT closure, the gross-margin percentage increase for both the quarter and first nine months was mostly due to favorable mix from higher-margin direct-to-consumer My Medic products.
- U.S. Segment PerformanceU.S. net sales increased 20% in the third quarter, with strong sales in the First Aid and Westcott cutting tool segments. Excluding My Medic, U.S. sales increased 10%. U.S. sales increased 17% for the first nine months, or 7% excluding My Medic, driven by higher sales across all product lines.
- Strong Back-to-School and Westcott ResultsBack-to-school sales were described as excellent, reflecting new promotional activity and strong sell-through in the mass-market channel. Management said Westcott benefited from the return of promotional activity, product innovation, and effective execution, while noting that comparisons also benefited from promotional activity that had been delayed or stopped in 2025.
- My Medic ContributionThe My Medic acquisition performed as planned, generating $4 million in quarterly net sales and a positive operating cash flow contribution.
- International GrowthEurope delivered a 7% increase in net sales in local currency during the third quarter and a 15% increase for the first nine months, partly due to the new line of cutting and sharpening tools, with solid performances from Westcott and First Aid. Canada increased 12% in local currency in the quarter and 8% year-to-date, mainly due to higher First Aid sales.
- SmartCompliance Product LaunchAcme introduced its latest SmartCompliance First Aid kit in September at the National Safety Conference. The kit includes integrated RFID technology and automatically generates replenishment orders for refills. Customer feedback was encouraging, and shipping is planned to begin in January 2027.
- Spill Magic Capacity ExpansionThe Spill Magic plant in Mount Pleasant, Tennessee, opened in March 2026 and is now fully operational. Increased capacity contributed to approximately 34% growth in the Spill Magic product line year to date. The company also installed highly automated production and filling equipment, and management said the plant is positioned for future growth.
- DMT Facility Restructuring and Expected SavingsAcme plans to close its small DMT facility in Marlborough, Massachusetts, during the fourth quarter after determining that it lacked sufficient scale or capacity to be a long-term asset and that production was not cost-effective. The company reserved $1 million, and savings are expected to be over $1 million annually beginning in January 2027.
- Strong Cash Generation and LiquidityManagement reported strong cash generation in 2026 and excellent liquidity. The company generated approximately $13 million in free cash flow during the 12-month period ended September 30, 2026, including tariff refunds.
- Continued Organic Growth and New BusinessNew business efforts in retail and industrial distribution are beginning to generate additional sales. Acme has already booked new First Aid business for 2027 and is seeing continued strength in cutting tools.
- Selective Acquisition StrategyAcme continues to evaluate acquisition opportunities and intends to pursue strategic transactions with a high likelihood of success. Management said the company is being careful, is not highly leveraged, and expects that there will probably be another deal within the next 12 months.
- First Aid Growth OpportunityManagement said First Aid represents approximately 70% of the company and has greater long-term organic growth opportunities. The segment also lends itself to consolidation, with Acme viewed as a natural buyer of competitors and adjacent businesses.
- Operational Efficiency Offsetting Cost IncreasesAcme reported increases in shipping costs, freight expenses, and inflation, but said these pressures are being offset by improved efficiency from automation and new equipment.
- Tax BenefitNet income for the first nine months benefited from approximately $400,000 of tax benefits resulting from stock option exercise.
- Positive Near-Term OutlookManagement expects the fourth quarter to be seasonally strong in both sales and earnings and projected a solid fourth quarter of 2026.
DE:UT1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.53- | 0.42 | ― | ― |
| Oct 27, 2026 | 2026 (Q3) | 0.660.72 | 0.42 | 73.91% (+0.31) | |
| Jul 23, 2026 | 2026 (Q2) | 0.401.10 | 1.05 | 5.17% (+0.05) | |
| Apr 23, 2026 | 2026 (Q1) | 0.430.22 | 0.37 | -41.46% (-0.15) | |
| Feb 26, 2026 | 2025 (Q4) | 0.380.42 | 0.37 | 12.20% (+0.05) | |
| Oct 21, 2025 | 2025 (Q3) | 0.490.42 | 0.49 | -14.81% (-0.07) | |
| Jul 23, 2025 | 2025 (Q2) | 0.451.05 | 0.99 | 6.42% (+0.06) | |
| Apr 17, 2025 | 2025 (Q1) | 0.480.37 | 0.35 | 5.13% (+0.02) | |
| Feb 28, 2025 | 2024 (Q4) | 0.440.37 | 0.36 | 2.50% (+0.01) | |
| Oct 18, 2024 | 2024 (Q3) | 0.660.49 | 0.52 | -6.90% (-0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

